{"id":62520,"date":"2026-01-21T04:06:21","date_gmt":"2026-01-21T03:06:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/"},"modified":"2026-01-21T04:06:21","modified_gmt":"2026-01-21T03:06:21","slug":"kkr-led-consortium-drives-further-investment-in-sylvan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/","title":{"rendered":"KKR-led Consortium Drives Further Investment in Sylvan"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the \u201cCompany\u201d), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan.<\/p>\n

<\/a>
<\/a><\/p>\n

\nFounded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential of fungal systems to create sustainable solutions to address global challenges in food, health, agriculture, and materials. Today, the Company operates multiple production facilities around the world and serves customers across 65 countries.<\/p>\n

\nThis latest investment marks KKR\u2019s continued commitment to supporting Sylvan\u2019s next phase of expansion, including increasing production capacity, strengthening R&D capabilities, advancing new high-growth product categories, and deepening the Company\u2019s presence across Asia\u2019s rapidly industrializing mushroom and bio-products markets.<\/p>\n

\nThe KKR-led investment also included commitments from global investors, including TPG NewQuest, who served as lead investor in a GP-led transaction alongside KKR to support Sylvan, in addition to Ping\u2019An Capital, China Post Insurance, Schroders Capital and Tsao Pao Chee. KKR is making its investment through its international and domestic funds, including its first Renminbi-denominated fund, which was established to facilitate investment by local investors.<\/p>\n

\nChris Sun, Partner and Head of China Private Equity at KKR<\/b>, said: \u201cSylvan has delivered sustained growth under our strategic partnership, including strong expansion and advances in R&D and strategic acquisitions. We have worked closely with management to broaden Sylvan\u2019s role in the global fungal biotechnology sector and beyond. KKR is pleased to welcome new investors from overseas and China to join us in supporting Sylvan to expand its platform and global reach.\u201d<\/p>\n

\nJackie Qi, CEO of Sylvan<\/b>, said: \u201cKKR has been a trusted partner for Sylvan through our development, and we are pleased to have their continued support. This investment allows us to accelerate our ambition to become a global leader in fungal biotechnology solutions across strategies and regions. With the support and expertise of our investors, we have faith in Sylvan\u2019s next phase of growth.\u201d<\/p>\n

\nAbout Sylvan<\/b><\/p>\n

\nSylvan is a fungal biotechnology company, unlocking the incredible potential of the Earth\u2019s fungi systems. We believe these resilient fungi, having evolved over millions of years, hold the key to overcoming many of the problems our planet faces today and into the future. Our goal is simple: harness the power of fungi and create sustainable solutions to address global challenges in food, health, agriculture, and materials.<\/p>\n

\nAbout KKR<\/b><\/p>\n

\nKKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR\u2019s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR\u2019s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR\u2019s website at www.kkr.com<\/a>. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group\u2019s website at www.globalatlantic.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please contact:<\/b><\/p>\n

\nS<\/b>ylvan<\/b>
Erica Wang
\n
Erica.Wang@sylvaninc.com<\/a><\/p>\n

\nKKR<\/b>
Wei Jun Ong
\n
Media@kkr.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the \u201cCompany\u201d), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62520","6":"format-standard","7":"category-industry"},"yoast_head":"\nKKR-led Consortium Drives Further Investment in Sylvan - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KKR-led Consortium Drives Further Investment in Sylvan - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the \u201cCompany\u201d), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-21T03:06:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260120305013\/en\/2696382\/22\/KKR_Logo_Jan_14.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"KKR-led Consortium Drives Further Investment in Sylvan\",\"datePublished\":\"2026-01-21T03:06:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/\"},\"wordCount\":609,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120305013\\\/en\\\/2696382\\\/22\\\/KKR_Logo_Jan_14.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/\",\"name\":\"KKR-led Consortium Drives Further Investment in Sylvan - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120305013\\\/en\\\/2696382\\\/22\\\/KKR_Logo_Jan_14.jpg\",\"datePublished\":\"2026-01-21T03:06:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120305013\\\/en\\\/2696382\\\/22\\\/KKR_Logo_Jan_14.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260120305013\\\/en\\\/2696382\\\/22\\\/KKR_Logo_Jan_14.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kkr-led-consortium-drives-further-investment-in-sylvan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KKR-led Consortium Drives Further Investment in Sylvan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KKR-led Consortium Drives Further Investment in Sylvan - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/","og_locale":"en_US","og_type":"article","og_title":"KKR-led Consortium Drives Further Investment in Sylvan - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the \u201cCompany\u201d), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-21T03:06:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260120305013\/en\/2696382\/22\/KKR_Logo_Jan_14.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"KKR-led Consortium Drives Further Investment in Sylvan","datePublished":"2026-01-21T03:06:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/"},"wordCount":609,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260120305013\/en\/2696382\/22\/KKR_Logo_Jan_14.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/","url":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/","name":"KKR-led Consortium Drives Further Investment in Sylvan - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260120305013\/en\/2696382\/22\/KKR_Logo_Jan_14.jpg","datePublished":"2026-01-21T03:06:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260120305013\/en\/2696382\/22\/KKR_Logo_Jan_14.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260120305013\/en\/2696382\/22\/KKR_Logo_Jan_14.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kkr-led-consortium-drives-further-investment-in-sylvan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"KKR-led Consortium Drives Further Investment in Sylvan"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62520"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62520\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}